Successful treatment of life-threatening melioidosis with activated protein C and meropenem

Area of Science:

• Infectious Diseases
• Critical Care Medicine
• Bacteriology

Background:

• Melioidosis, caused by Burkholderia pseudomallei, is endemic in Southeast Asia and Northern Australia.
• A typhoon-related outbreak in Taiwan in 2005 highlighted the severity of melioidosis, often leading to high mortality.
• Bacteremic pneumonia and septic shock are critical complications associated with high melioidosis mortality.

Observation:

• A patient presented with rapidly progressing, life-threatening melioidosis.
• The patient developed severe bacteremic pneumonia, acute respiratory distress syndrome (ARDS), septic shock, and multiple organ dysfunction.
• This clinical scenario represents a severe manifestation of melioidosis.

Findings:

• Successful treatment was achieved using a combination of meropenem and recombinant human activated protein C (rhAPC).
• This marks the first reported use of rhAPC in managing life-threatening melioidosis.
• The patient's recovery demonstrates the potential efficacy of rhAPC in critical melioidosis cases.

Implications:

• Recombinant human activated protein C (rhAPC) may offer a novel therapeutic option for severe melioidosis.
• This case suggests rhAPC could be beneficial in reducing mortality associated with severe septic shock in melioidosis.
• Further research into rhAPC's role in treating severe bacterial infections like melioidosis is warranted.